Purple Biotech (PPBT) 6-K: Nasdaq Minimum Bid Price Notification

Purple Biotech Ltd. (PPBT) furnished a Form 6-K reporting that on October 20, 2025 it issued a press release titled “Purple Biotech Announces Receipt of Nasdaq Regarding Minimum Bid Price Notification.” The press release is included as Exhibit 99.1.

Rhea-AI Filing Summary

Purple Biotech Ltd. (PPBT) furnished a Form 6-K reporting that on October 20, 2025 it issued a press release titled “Purple Biotech Announces Receipt of Nasdaq Regarding Minimum Bid Price Notification.”

The press release is included as Exhibit 99.1. This filing serves as a notice to investors about the company’s receipt of a Nasdaq minimum bid price notification and provides the related disclosure via the attached exhibit.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Purple Biotech (PPBT) file?

Purple Biotech filed a Form 6-K.

What is the subject of the PPBT 6-K?

It reports a press release about a Nasdaq minimum bid price notification.

When was the press release issued by PPBT?

The press release was issued on October 20, 2025.

What is included as an exhibit in this filing?

Exhibit 99.1 contains the press release titled “Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification.”

What is Purple Biotech’s ticker symbol?

Purple Biotech trades under the symbol PPBT.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/20/2025 - 04:01 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of October 2025

Commission File Number: 001-37643

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Purple Biotech

On October 20 , 2025, Purple Biotech Ltd. (the “Company” or the “Registrant”) issued a press release “Purple Biotech Announces Receipt of Nasdaq Regarding Minimum Bid Price Notification”, which is attached hereto as Exhibit 99.1.

Exhibit
99.1		Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

October 20, 2025	PURPLE BIOTECH LTD.
	By:	/s/ Gil Efron
		Gil Efron
		Chief Executive Officer

2